Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib

Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib

Gastrointestinal Stromal Tumor

Terminated

3

Start Date 08/15/2008

Age of Trial (yrs) 15.7

Gleevec-resistant

HSP90 inhibitor

Destroy KIT

Specifically GIST and only GIST

IPI-504-06

Infinity MedImmune AstraZeneca

GIST Phase 3 Team http://www.ringtrial.com/

RINGtrialinfo@infi.com

877-504-4634

Randomized

IV Intravenous

CAMBRIDGE, Mass., April 15, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that, based on the recommendation of its independent data monitoring committee (IDMC), Infinity has elected to terminate the RING trial, a double-blind, placebo-controlled international Phase 3 registration trial of IPI-504 (retaspimycin hydrochloride) in patients with refractory gastrointestinal stromal tumors (GIST).

The IDMC's recommendation yesterday evening to halt the trial was based on an early review of safety data from the first 46 patients enrolled in the study, which showed a higher than anticipated mortality rate among patients enrolled in the treatment arm.

IPI-504-06 was a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of IPI-504, an Hsp90 inhibitor made by Infinity, as compared to placebo in patients with metastatic and/or unresectable GIST following failure of at least imatinib and sunitinib.

Trial design called for patients to be randomized using a 2:1 ratio to receive either IPI-504 or placebo.